Last updated 9 days ago
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
208 patients around the world
Available in Spain, Argentina, United States
Bristol-Myers Squibb
12Research sites
208Patients around the world
This study is for people with
Heart failure
Requirements for the patient
To 85 Years
All Gender
Medical requirements
- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability.
- Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant.Other protocol-defined Inclusion/Exclusion criteria apply.
Sites
Instituto Médico Damic S.R.L.
Recruiting
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Recruiting
Sanatorio Duarte Quiros - Córdoba
Recruiting
Instituto de Cardiología SRL - Tucumán
Recruiting
Centro Cardiovascular Salta
Recruiting
Investigaciones Médicas IMOBA SRL
Recruiting
Centro de Investigaciones Clínicas del Litoral SRL
Recruiting
Instituto Cardiovascular de Rosario
Recruiting
Instituto de Investigaciones Clínicas Zárate
Recruiting
Clínica Privada Del Prado SRL - Córdoba
Recruiting
StudyAURORA-HFpEF
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
Heart failure
Requirements
To 85 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06122779
